Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 34Cyclophosphamide 30Mycophenolic Acid 25Whole-Body Irradiation 22Cyclosporine 22Tacrolimus 21Busulfan 18Methotrexate 17Antilymphocyte Serum 16Radiotherapy 14Flow Cytometry 13Filgrastim 13Etoposide 13Vorinostat 10Methylprednisolone 10Bortezomib 10Bexarotene 10Melphalan 9Therapeutics 8Rituximab 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Lenalidomide 8Gemcitabine 8romidepsin 7fludarabine 6Cord Blood Stem Cell Transplantation 6Brentuximab Vedotin 6tanespimycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mycosis Fungoides × trastuzumab biosimilar HLX02 × Dermatologic × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡